AZD8330 First Time in Man in Patients With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00454090
Recruitment Status : Completed
First Posted : March 29, 2007
Last Update Posted : August 24, 2011
Information provided by:

Brief Summary:
The primary purpose of this protocol is to investigate the safety and tolerability of AZD8330 (ARRY-424704) in patients with Advanced Malignancies

Condition or disease Intervention/treatment Phase
Cancer Drug: AZD8330 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 83 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies
Study Start Date : March 2007
Actual Primary Completion Date : October 2010
Actual Study Completion Date : March 2011

Intervention Details:
  • Drug: AZD8330
    oral tablet
    Other Name: ARRY-424704

Primary Outcome Measures :
  1. To assess safety and tolerability of AZD8330 in patient with advanced malignancies.
  2. Outcome variables: Adverse Events, Clinical Chemistry, Haematology, Urinalysis, Vital signs, MUGA scans/echocardiography, ECGs, Ophthalmologic examination, O2 saturation

Secondary Outcome Measures :
  1. To determine the PK of AZD8330.
  2. To investigate possible PD/PK relationships
  3. To investigate effect of AZD8330 on pERK in PBMCs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cancer which is refractory to standard therapies, or no therapies exist;

Exclusion Criteria:

  • Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start;
  • Hasn't participated in investigation drug study within 30 days;
  • Brain metastases/spinal cord compression unless treated and stable,
  • Off steroids/anticonvulsants.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00454090

United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
United States, Texas
Research Site
Houston, Texas, United States
Research Site
Oslo, Norway
Sponsors and Collaborators
Study Director: Emerging Oncology Medical Science Director, MD AstraZeneca

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: MSD, AstraZeneca Identifier: NCT00454090     History of Changes
Other Study ID Numbers: D1536C00001
First Posted: March 29, 2007    Key Record Dates
Last Update Posted: August 24, 2011
Last Verified: August 2011

Keywords provided by AstraZeneca:
Advanced Malignancies

Additional relevant MeSH terms: